aap Implantate AG: directors' dealings · Germany · BaFin

About aap Implantate AG

aap Implantate AG is a German medical technology company listed on the regulated market of the Frankfurt Stock Exchange, with trading on Xetra/Frankfurt (DAX/MDAX/SDAX) under the ticker AAQ1.DE. The company is headquartered in Berlin, Germany, and operates as a focused specialist in orthopedic trauma care. Founded in 1990, aap has built its business around implants and fixation systems used primarily for fracture treatment and reconstructive surgery, with a group structure that includes operating entities in Germany and the United States. ([aap.de](https://www.aap.de/company?utm_source=openai)) Strategically, aap presents itself as a pure player in trauma, meaning that its portfolio is concentrated on a narrow but technically demanding segment of orthopedics rather than spread across broad medtech categories. Its flagship product family is LOQTEQ®, an anatomical plating system built around a patented locking-compression technology. The product range also includes plates and screws for osteosynthesis and related trauma applications. This specialization can be attractive in a market where surgical performance, regulatory compliance, and hospital relationships matter more than scale alone. ([aap.de](https://www.aap.de/products?utm_source=openai)) Commercially, the company sells directly to hospitals, purchasing groups, and hospital networks, while also using distributors. Its geographic footprint is international, with a core base in Europe and active exposure to the US, Asia-Pacific, and Latin America. Against much larger global orthopedic and medtech players, aap’s competitive positioning is that of a niche innovator: smaller in scale, but differentiated by product design, intellectual-property protection, and a targeted route-to-market strategy. ([stockanalysis.com](https://stockanalysis.com/quote/etr/AAQ1/?utm_source=openai)) Recent developments have been important for the investment case. In 2024, the company reported improved operating performance; in June 2025 it said revenue for 2024 was EUR 12.2 million and that group EBITDA had improved materially versus the prior year. In 2025, aap highlighted the successful completion of its human clinical trial for antibacterial silver implant technology, with the study report expected by the end of 2025 and MDR and US FDA approval work ongoing. Management also extended CEO Rubino Di Girolamo’s mandate through the end of 2028. For investors, aap remains a specialized medtech story driven by regulatory milestones, commercialization execution, and the potential monetization of its antibacterial implant platform. ([aap.de](https://www.aap.de/investor-relations/publications/press-releases?utm_source=openai))